{
    "title": "108_s1773",
    "content": "Biotechnology Future Investment Expansion Act of 2003 - Amends the Internal Revenue Code to provide that in the case of a biomedical research corporation, any owner shift involving a five-percent shareholder which occurs as the result of a qualified investment during the testing period shall be treated as occurring before the testing period. Defines: (1) biomedical research corporation as a domestic corporation not in bankruptcy which has a drug or biologic in certain clinical trials. And (2) qualified investment as a stock acquisition in a biomedical research corporation acquired in cash at its original issue. Requires a biomedical research corporation to meet a five-year expenditure test with respect to any qualified investment."
}